Lilly's Triple Agonist, Retatrutide, Successful in Two Additional Phase 3 Obesity Trials, Delivering Significant Improvements in Weight and A1C
Phase 3positiveRetatrutideZepboundFoundayoPositive
AI Analysis
Summary
Eli Lilly announced positive topline results from two pivotal Phase 3 trials (TRIUMPH-2 and TRIUMPH-3) for its triple agonist retatrutide, demonstrating significant improvements in weight loss and A1C in obesity patients.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
TRIUMPH-2 and TRIUMPH-3 Phase 3 trials met endpoints with significant improvements in weight and A1C
Importance:8/10
Sentiment:
0.85
Phase 3 resultsobesityretatrutidetriple agonistweight lossA1C improvement
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on July 23, 2026 9:07 PM